Evidence map›Paper›PMID 34152439›Full record

ArticleCancer immunology, immunotherapy : CII2022

Latency-associated peptide identifies therapeutically resistant muscle-invasive bladder cancer with poor prognosis.

Ruiting Ye, Han Zeng, Zhaopei Liu, Kaifeng Jin, Chunnan Liu, Sen Yan, Yanze Yu, Runze You, Hongyi Zhang, Yuan Chang and 6 more

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer immunology, immunotherapy : CII, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.6field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 5 citations in OpenAlex.

  1. ARID1A Loss plus CD8+ T-Cell Infiltration Associate with Favorable Clinical Outcomes in Urothelial Carcinoma.Clinical cancer research : an official journal of the American Association for Cancer Research · 2025
    Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 5 institutions in 1 country.

Ruiting Ye *Department of Urology, Fudan University Shanghai Cancer Center, Shanghai, 200032, China.
Han Zeng *Department of Biochemistry and Molecular Biology, School of Basic Medical Sciences, Fudan University, Shanghai, 200032, China.
Zhaopei Liu *Department of Biochemistry and Molecular Biology, School of Basic Medical Sciences, Fudan University, Shanghai, 200032, China.
Kaifeng Jin *Department of Biochemistry and Molecular Biology, School of Basic Medical Sciences, Fudan University, Shanghai, 200032, China.
Chunnan LiuDepartment of Biochemistry and Molecular Biology, School of Basic Medical Sciences, Fudan University, Shanghai, 200032, China.
Sen YanDepartment of Biochemistry and Molecular Biology, School of Basic Medical Sciences, Fudan University, Shanghai, 200032, China.
Yanze YuDepartment of Biochemistry and Molecular Biology, School of Basic Medical Sciences, Fudan University, Shanghai, 200032, China.
Runze YouDepartment of Biochemistry and Molecular Biology, School of Basic Medical Sciences, Fudan University, Shanghai, 200032, China.
Hongyi ZhangDepartment of Biochemistry and Molecular Biology, School of Basic Medical Sciences, Fudan University, Shanghai, 200032, China.
Yuan ChangDepartment of Urology, Fudan University Shanghai Cancer Center, Shanghai, 200032, China. changyuan0802@163.com.
Yiwei WangDepartment of Urology, Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Li LiuDepartment of Urology, Zhongshan Hospital, Fudan University, Shanghai, 200032, China.
Yu ZhuDepartment of Urology, Fudan University Shanghai Cancer Center, Shanghai, 200032, China.
Jiejie XuDepartment of Biochemistry and Molecular Biology, School of Basic Medical Sciences, Fudan University, Shanghai, 200032, China. jjxufdu@fudan.edu.cn.ORCID http://orcid.org/0000-0001-7431-9063
Le XuDepartment of Urology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200025, China. xl11887@rjh.com.cn.
Zewei WangDepartment of Urology, Zhongshan Hospital, Fudan University, Shanghai, 200032, China. zwwang12@fudan.edu.cn.
Fudan University · CNFudan University Shanghai Cancer Center · CNShanghai Jiao Tong University · CNSun Yat-sen University · CNShanghai Medical College of Fudan University · CN

Funding

Fudan University Shanghai Cancer Center for Outstanding Youth Scholars Foundation YJYQ201802National Natural Science Foundation of China 31770851, 81872082, 81902556, 82002670Shanghai Municipal Commission of Health and Family Planning Program 20174Y0042, 201840168, 20184Y0151Shanghai Municipal Natural Science Foundation 19ZR1431800Shanghai Sailing Program 18YF1404500, 19YF1427200, 21YF1407000
6 · The paper itself

Abstract

backgroundLatency-associated peptide (LAP) was identified as crucial immune regulator in tumor microenvironment (TME) in recent researches. In this study, we aimed to estimate the predictive value of LAP expression for clinical survival and therapeutic response in muscle-invasive bladder cancer (MIBC).

methodsOur study encompassed 140 MIBC patients from Zhongshan Hospital (ZSHS cohort), 401 patients from The Cancer Genome Atlas (TCGA cohort) and 195 patients received PDL1 blockade from IMvigor210 trial. Survival analyses were conducted through Kaplan-Meier curve and Cox regression model. LAP expression and its association with immune contexture were evaluated in ZSHS and TCGA cohort.

resultsWe found that high intratumoral LAP

conclusionsLAP expression was correlated with patients' inferior prognosis, ACT-tolerance and an immunoevasive TME with exhausted CD8

Indexed as

Drug Resistance, NeoplasmTumor MicroenvironmentCD8-Positive T-LymphocytesChemotherapy, AdjuvantFollow-Up StudiesHumansImmune Checkpoint InhibitorsMuscle NeoplasmsPeptidesPrognosisProtein PrecursorsRetrospective StudiesSurvival RateTransforming Growth Factor betaTumor EscapeUrinary Bladder NeoplasmsImmune Checkpoint Inhibitorslatency-associated propeptide, TGF-betaPeptidesProtein PrecursorsTransforming Growth Factor betaAdjuvant chemotherapyClinical outcomeImmune checkpoint inhibitorsLatency-associated peptideMuscle-invasive bladder cancerTumor microenvironment

Identifiers

PMID34152439
PMCPMC10992091
OpenAlexW3173857028

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.